Mon. May 25th, 2026
Spread the love

There was a time when Lance Armstrong’s downfall in cycling was
going to not only equal a lifetime of shame — but also financial
hardship.

Faced with lawsuits seeking tens of millions of dollars in
damages for his fraudulent life as a doping cheat — and an
aggressively litigious pursuer of anyone who suggested otherwise —
Armstrong’s was in strife.

But in his first US television interview since sitting down with
Oprah Winfrey in 2013, the cancer survivor who captured the
imagination of the world while winning seven Tour de France titles
— then had them stripped in the biggest doping scandal in history —
has revealed he’s more than landed on his feet.

Now 47, Armstrong reached a $5 million settlement with the US
federal government in April when they could have sought up to $100
million if the suit went to trial. But that doesn’t appear to come
close to the windfall he’s made on an early investment in Uber.

The Texas native invested $100,000 with a venture capital firm
in 2009, the bulk of which went to the ride-sharing app that he
says was valued at just $3.7 million at the time.

Today, as the company prepares for its IPO, banks have valued it
as high as $120 billion. That could make Armstrong’s shares worth
more than $3 billion, but he declined to reveal the exact figure,
simply telling CNBC[1] the number is “too
good to be true” and “it’s saved our family.”

Armstrong’s bonanza was a giant stroke of luck after he received
a phone call from former Google employee and now billionaire
investor Chris Sacca.

“He was starting his own venture capital fund, Lowercase
Capital, and he called me saying, ‘I’m looking for investors, would
you invest?’” Armstrong said.

“I’m thinking to myself, ‘This guy has a huge personality but
he’s also very smart and very well connected.’ So I invested in
Chris Sacca. I didn’t even know that he did Uber. I thought he was
buying up a bunch of Twitter shares from employees or former
employees, and the biggest investment in (the) Lowercase fund one
was Uber.”

Armstrong isn’t apologizing for his financial success, nor does
he feel he was let “off easy” in his settlement with the US
government.

“I didn’t think I got off scot-free because the settlement for
$5 million was probably the 10th settlement … once you total up all
of it — loss of guaranteed income, legal fees and settlements — it
came to $111 million,” he said. “So I don’t feel like I got off
easy.”

Armstrong: Why I remain so hated

Armstrong has a pretty solid spot in the pantheon of most hated
sports figures, but he doesn’t sound thrilled with that — or his
company.

The former cyclist isn’t quite embracing his place in sports
lore. “I do think there’s a double standard,” he said. “But I’m OK
with it.”

After his 2013 confession to Winfrey, Armstrong received strong
backlash, with a healthy amount of anger toward him lingering to
this day.

He puts it down to the way he so viciously attacked anyone who
questioned him about doping — rather than the cheating itself.

“If you polled the world, the first issue — doping in the sport
of cycling — most people have enough knowledge now to know it
looked like everybody did it,” he said.

“That isn’t the issue for people. The issue is how I so
aggressively defended myself. Being litigious, going after
people.

“This idea of bullying … I say it all the time, when I watch old
clips … the way I acted — if I saw my children act that way, it
would be a very rough conversation.”

Banned from cycling for life in 2012, Armstrong invoked another
famous cheater in Alex Rodriguez, the former New York Yankees
superstar who received a one-year ban for his role in Biogenesis,
but has been able to reclaim a positive spot in the public eye
years later.

It’s a luxury Armstrong hasn’t been afforded, despite his
Livestrong brand’s work for cancer research.

“Alex Rodriguez didn’t raise half a billion dollars and try to
save a bunch of people’s lives,” Armstrong said. “That’s kind of
the irony of this. Look, it’s great when somebody hits home runs
and maybe does an event here and there for the Girls and Boys Club.
This story held a place in people’s hearts and minds that was way
beyond those guys.”

Armstrong on that Trump tweet

Armstrong received “tens of thousands” of responses to the Oprah
interview in 2013, but one of the more memorable reactions was a
tweet by Donald Trump.

Armstrong saw the tweet. “This is six years ago, so Donald Trump
was just a loudmouth out trying to get attention and that was in a
sea of tens of thousands of those, so he was just another person,”
Armstrong said.

“Now he’s our president, somehow … whatever. He’s half-right.
He’s going to cost himself a lot of money — we know that happened.
And a lifetime of failure … well, I don’t know who judges people’s
lifetimes, whether they’re failures or successes or just OK. I
don’t feel like a failure and I’ve never felt like a failure since
then.”

References

  1. ^
    telling
    CNBC
    (www.cnbc.com)
  2. ^
    January 18, 2013
    (twitter.com)

Read more

By admin

You missed

From Tramadol to Canadian to Exol-5 The New Drug Destroying Nigerian Youths An Investigative Article .From Tramadol to Canadian to Exol-5: The New Drug Destroying Nigerian Youths An Investigative Report on the Shifting Landscape of Substance Abuse in Nigeria Nigeria faces a severe and evolving drug crisis, particularly among its youth. What began with the widespread abuse of Tramadol has progressed through mixtures like “Canadian” to newer pharmaceutical diversions such as Exol-5. This shift reflects deeper issues: easy access to prescription drugs, weak regulation, socioeconomic pressures, and aggressive street-level marketing. NDLEA operations and health studies reveal a public health emergency that threatens an entire generation. Phase 1: The Tramadol Epidemic (2010s–Early 2020s) Tramadol, a synthetic opioid prescribed for moderate to severe pain, became Nigeria’s most notorious street drug. Cheap, potent, and widely smuggled (often from India and other Asian countries), it offered users energy, euphoria, and pain relief — appealing to commercial drivers, laborers, students, and young men seeking confidence or stamina. Scale of the Problem: Millions of tablets seized annually by NDLEA. High prevalence among young males aged 15–35. Linked to increased crime, sexual violence, organ damage (kidney failure, seizures), and mental health breakdowns. Contributed to broader opioid misuse alongside codeine cough syrups. Government responses included tighter import controls and public awareness campaigns, but these only displaced demand to other substances rather than eliminating it. Phase 2: The Rise of “Canadian” (Mid-2020s) “Canadian” or “Canadian Loud” emerged as a popular code for high-grade cannabis (often indica-dominant strains) or cannabis mixed with other synthetics. It gained traction as users sought alternatives or combinations to Tramadol’s effects. This phase marked a move toward imported or locally cultivated premium weed, sometimes laced with stronger chemicals. Youths in urban centers like Lagos, Kano, Jos, and Onitsha embraced it for its perceived “cleaner” high compared to opioids. However, it fueled polydrug use — combining cannabis with opioids, sedatives, or alcohol — amplifying health risks. Phase 3: Exol-5 – The Current Threat (2024–2026) Exol-5 (Benzhexol Hydrochloride / Trihexyphenidyl 5mg), originally a prescription medication for Parkinson’s disease and drug-induced movement disorders, has become the latest pharmaceutical being heavily abused. Why Exol-5? Euphoric Effects: Users report intense euphoria, hallucinations, and a sense of detachment — making it attractive as a cheap “upper” or escape. Accessibility: Sold over-the-counter or on the black market despite being a controlled prescription drug. NDLEA has seized millions of pills in single operations (e.g., 3.1 million pills in Kano in late 2024, and over 5.6 million combined with Tramadol in other busts). Street Names: Exol, Artane, Benzhexol, “Farin Mallam” (in Northern Nigeria). Demographics: Prevalent among youths, laborers, and even psychiatric patients who divert prescriptions. Studies show abuse rates as high as 25% among certain outpatient groups. Health Consequences: Anticholinergic toxicity: Confusion, dry mouth, blurred vision, urinary retention, constipation, and in high doses — delirium, psychosis, seizures, and heart issues. Long-term: Cognitive impairment, addiction, exacerbated mental health disorders. Often mixed with Tramadol, codeine, or cannabis, creating dangerous synergies. In cities like Jos, Exol-5 sits alongside diazepam, Rohypnol, and Tramadol on street markets, easily available to teenagers and young adults. Why This Evolution Continues Supply-Side Failures: Porous borders, corrupt officials, and overproduction of pharmaceuticals enable diversion. Demand Drivers: Unemployment, poverty, peer pressure, trauma, and the pursuit of performance enhancement (e.g., for “hustle” culture). Weak Regulation: Many pharmacies sell restricted drugs without prescriptions. Online and street vendors fill gaps. Displacement Effect: Cracking down on one substance (Tramadol/codeine) pushes users and dealers toward the next available option. NDLEA reports ongoing large seizures, but the problem persists due to high profitability and low risk for mid-level distributors. Broader Impacts on Nigerian Youths Education: Increased dropout rates and poor academic performance. Mental Health: Rising cases of psychosis and depression. Economy: Lost productivity among the working-age population. Crime and Violence: Drug-fueled robberies, cultism, and family breakdowns. Public Health System Strain: Overburdened hospitals treating overdoses and chronic complications. Young people aged 15–39 remain the hardest hit, with national surveys showing drug use prevalence significantly above global averages. What Must Be Done Stronger Enforcement: Consistent prosecution of corrupt enablers and large-scale traffickers. Regulation: Crackdown on rogue pharmacies and better tracking of prescription drugs. Prevention & Rehabilitation: School programs, community outreach, and expanded treatment centers (currently woefully inadequate). Economic Alternatives: Address root causes like youth unemployment. Public Awareness: Honest campaigns highlighting real dangers of “Exol-5” and similar drugs. Conclusion From Tramadol’s opioid grip to “Canadian” cannabis culture and now Exol-5’s anticholinergic highs, Nigeria’s drug crisis is mutating faster than responses can contain it. Exol-5 represents the dangerous new frontier — a legitimate medicine turned youth destroyer due to misuse and greed. Without urgent, multi-layered intervention — combining supply disruption, demand reduction, and socioeconomic support — an entire generation risks being lost to addiction. The time for half-measures is over. Nigeria’s future depends on winning this fight.